Company Profile
Indaptus Therapeutics Stock Price, News & Catalysts
- Ticker:
- INDP
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.00 USD (-6.54%)
Close
Last updated: August 17, 2026
243M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, INDP closed down 6.54% at $1.00. No new same-company headline was identified in the current news window.
Company overview
Immunotherapy Research Company
Indaptus Therapeutics developed the Decoy platform, a systemic immunotherapy approach designed to activate multiple innate and adaptive immune pathways.
Decoy20
Decoy20 is a killed, attenuated bacterial product intended to stimulate broad antitumor immunity. Indaptus has discontinued enrollment and currently has no patients in active Decoy20 clinical studies.
Strategic Review
The company has reduced Decoy20 development activities and is evaluating research collaborations, strategic investments, acquisitions, and other potential business combinations.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Indaptus Therapeutics (INDP)?
Indaptus Therapeutics (INDP) most recently closed at 1.00 USD, a -6.54% move versus the previous session.
What is the market cap of Indaptus Therapeutics (INDP)?
Indaptus Therapeutics currently has a market capitalization of 243M USD on BioPharmSignal.
What does Indaptus Therapeutics do?
Immunotherapy Research Company Indaptus Therapeutics developed the Decoy platform, a systemic immunotherapy approach designed to activate multiple innate and adaptive immune pathways. Decoy20 Decoy20 is a killed, attenuated bacterial product intended to stimulate broad antitumor immunity. Indaptus has discontinued enrollment and currently has no patients in...
On which exchange is INDP stock listed?
Indaptus Therapeutics (INDP) is associated with NASDAQ, United States, Biopharma.
What is Immunotherapy?
Immunotherapy Research Company Indaptus Therapeutics developed the Decoy platform, a systemic immunotherapy approach designed to activate multiple innate and adaptive immune pathways.
Which conditions is Indaptus Therapeutics targeting with Immunotherapy?
Immunotherapy Research Company Indaptus Therapeutics developed the Decoy platform, a systemic immunotherapy approach designed to activate multiple innate and adaptive immune pathways. Decoy20 Decoy20 is a killed, attenuated bacterial product intended to stimulate broad antitumor immunity. Indaptus has discontinued enrollment and currently has no patients in...
What is Research?
Immunotherapy Research Company Indaptus Therapeutics developed the Decoy platform, a systemic immunotherapy approach designed to activate multiple innate and adaptive immune pathways.
What is Indaptus?
Immunotherapy Research Company Indaptus Therapeutics developed the Decoy platform, a systemic immunotherapy approach designed to activate multiple innate and adaptive immune pathways.